PAMAM dendrimers functionalised with an anti-TNF α antibody and chondroitin sulphate for treatment of rheumatoid arthritis

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Facile Synthesis of Cross-linked Hyperbranched Polyamidoamines Dendrimers for Efficient Hg(Ⅱ) Removal From Water

“…The FT-IR spectra of HPAMAM-ECH and HPAMAM-EGDE were showed in Figure 1A and Figure 1B , respectively. It can be observed that the absorption peaks around 3284 and 1640 cm −1 in HPAMAM, which correspond to the N-H stretching vibration of amino and C=O stretching vibration of amide ( Oliveira et al, 2021 ), respectively. After crosslinking with ECH, the stretching vibration peak of C=O were weakened and the C-O-C stretching vibration appeared at 1073 cm −1 ( Abdulhameed et al, 2019 ), which indicated the successful crosslinking between HPAMAM and ECH.…”

Bioengineered Nanoparticles Loaded-Hydrogels to Target TNF Alpha in Inflammatory Diseases

“…Mouse monoclonal antibody [2C8] (26,000 g mol −1 ) (ab8348, Abcam, Cambridge, UK) was linked to CS/PAMAM dendrimer NPs previously produced by the authors [ 25 ]. The linkage was obtained through a typical carbodiimide chemistry reaction.…”

“…In previous works, Tyramine-Gellan Gum (Ty-GG) hydrogels [ 23 ] and Tyramine-Gellan Gum/Silk Fibroin (Ty-GG/SF) hydrogels [ 24 ] showed good resistance to degradation, high mechanical strength, and a suitable drug controlled release for treating inflammatory conditions such as RA. Monoclonal anti-TNF α antibody (anti-TNF α Ab) linked to chondroitin sulfate (CS) modified poly(amidoamine) (CS/PAMAM) dendrimer nanoparticles (NPs) were developed and demonstrated a more targeted and effective therapeutic effect for the management of RA [ 25 ]. Herein, with the aforementioned in mind, it was hypothesized that by combining the two approaches, an improved delivery system would be achieved with a sustained release that would last for longer periods.…”

Modulation of inflammation by anti-TNF α mAb-dendrimer nanoparticles loaded in tyramine-modified gellan gum hydrogels in a cartilage-on-a-chip model

“…Anti-TNFa mAb-CS/PAMAM dendrimer NPs and Ty-GG were produced as previously described. 27,28 Herein, these systems were used to obtain anti-TNFa mAb-CS/PAMAM dendrimer NPs loaded-Ty-GG hydrogel. The hydrogel was prepared by mixing 1% (w/v) of Ty-GG solution with anti-TNFa mAb-CS/PAMAM dendrimer NPs at a final concentration of 0.5 mg mL À1 .…”

“…22 The use of microfluidic-based technology thus can address the handicaps between in vitro and in vivo models presenting new promising approaches to research in medicine. 23,24 In our previous work, monoclonal anti-TNFa antibody (anti-TNFa mAb) linked to chondroitin sulfate (CS) modified poly(amidoamine) (CS/PAMAM) dendrimer nanoparticles (NPs) 25 and loaded into Tyramine-Gellan Gum (Ty-GG) hydrogels were developed as a promising drug delivery vehicle to improve therapeutic efficacy in the treatment of inflammatory conditions such as RA. The therapeutic efficacy was evaluated using an inflammation in vitro model under standard static conditions and dynamic conditions using a bioreactor.…”